TIMOTHY CLARK

The scoring of preventive health savings including all provisions of S1422 and HR 2663 "Preventative Health Savings Act"

International intellectual property issues; and all provisions of S 1720 "Patent Transparency and Improvements Act of 2013"

International intellectual property issues; and all provisions of S 1720 "Patent Transparency and Improvements Act of 2013"

Education and awareness of the 2013-2014 influenza season; education and awareness of pandemic and biodefense funding, including policy ramifications of recent BARDA contract awards; education and awareness of Dengue; S1871 "Sustainable Growth Rate (SGR) Repeal and Medicare Beneficiary Access Improvement Act of 2013"; and all provisions of HR1024 a "Medication Therapy Management Empowerment Act of 2013"; all provisions of HR3890 and S1932 "Better Care, Lower Cost Act"; issues related to thecontinued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; general issues related to FDA and NIH funding; all provisions of HR 2985 "Combination Drug Development Incentive Act of 2013"; and awareness and education about Sanofi's Access to Medicines Program

Education and awareness of the 2013-2014 influenza season; education and awareness of pandemic and biodefense funding, including policy ramifications of recent BARDA contract awards; education and awareness of Dengue; S1871 "Sustainable Growth Rate (SGR) Repeal and Medicare Beneficiary Access Improvement Act of 2013"; and all provisions of HR1024 a "Medication Therapy Management Empowerment Act of 2013"; all provisions of HR3890 and S1932 "Better Care, Lower Cost Act"; issues related to thecontinued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; general issues related to FDA and NIH funding; all provisions of HR 2985 "Combination Drug Development Incentive Act of 2013"; and awareness and education about Sanofi's Access to Medicines Program

Education and awareness of the 2013-2014 influenza season; education and awareness of pandemic and biodefense funding, including policy ramifications of recent BARDA contract awards; education and awareness of Dengue; general issues related to NIH funding; all provisions of HR 2094 "School Access to Emergency Epinephrine Act"; all provisions of HR2985 "The Combination Drug Development Incentive Act"; S1871 "Sustainable Growth Rate (SGR) Repeal and Medicare Beneficiary Access Improvement Act of2013"; and all provisions of HR1024 and S557 "Medication Therapy Management Empowerment Act of 2013"

Education and awareness of the 2013-2014 influenza season; education and awareness of pandemic and biodefense funding, including policy ramifications of recent BARDA contract awards; education and awareness of Dengue; general issues related to NIH funding; all provisions of HR 2094 "School Access to Emergency Epinephrine Act"; all provisions of HR2985 "The Combination Drug Development Incentive Act"; S1871 "Sustainable Growth Rate (SGR) Repeal and Medicare Beneficiary Access Improvement Act of2013"; and all provisions of HR1024 and S557 "Medication Therapy Management Empowerment Act of 2013"

Education and awareness of the 2013-2014 influenza season; education and awareness of pandemic and biodefense funding, including policy ramifications of recent BARDA contract awards; education and awareness of dengue; general issues related to FDA funding; general issues related to NIH funding; general issues related to diabetes awareness; all provisions of HR 2094 "School Access to Emergency Epinephrine Act"; and issues related to the continued over-the-counter availability of allergy, cough and coldmedicines that contain pseudoephedrine

The scoring of preventive health savings including all provisions of S1422 and HR 2663 "Preventative Health Savings Act" and H.J.Res.59 - Continuing Appropriations Resolution, 2014, including funding for FDA.

Education and awareness of the 2013-2014 influenza season; education and awareness of pandemic and biodefense funding, including policy ramifications of recent BARDA contract awards; education and awareness of Dengue; general issues related to NIH funding; all provisions of HR 2094 "School Access to Emergency Epinephrine Act"; all provisions of HR2985 "The Combination Drug Development Incentive Act"; S1871 "Sustainable Growth Rate (SGR) Repeal and Medicare Beneficiary Access Improvement Act of2013"; and all provisions of HR1024 and S557 "Medication Therapy Management Empowerment Act of 2013"

All provisions of HR 3204 "Drug Quality and Security Act" and efforts to seek support for inclusion on the Department of Commerce Manufacturing Council

S. 77 "Prescription Drug and Health Improvement Act of 2013" - all provisions; S117, "Medicare Prescription Drug Price Negotiation Act of 2013" - all provisions; issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; education and awareness of the 2012-2013 influenza season; education and awareness of pandemic and biodefense funding; education and awareness of dengue; FDA funding; reauthorization of Pandemic and All HazardsPreparation Act; general issues related to the importation of pharmaceutical products; issues related to chronic disease treatment adherence with the CMS Innovation Center; general issues related to School Access to Emergency Ephinephrine; and issues related to the data exclusivity period for generic biologics.

S. 77 "Prescription Drug and Health Improvement Act of 2013" - all provisions; S117, "Medicare Prescription Drug Price Negotiation Act of 2013" - all provisions; issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; education and awareness of the 2012-2013 influenza season; education and awareness of pandemic and biodefense funding; education and awareness of dengue; FDA funding; reauthorization of Pandemic and All HazardsPreparation Act; general issues related to the importation of pharmaceutical products; issues related to chronic disease treatment adherence with the CMS Innovation Center; general issues related to School Access to Emergency Ephinephrine; and issues related to the data exclusivity period for generic biologics.

The scoring of preventive health savings including all provisions of S1422 and HR 2663 "Preventative Health Savings Act" and H.J.Res.59 - Continuing Appropriations Resolution, 2014, including funding for FDA.

Education and awareness of the 2013-2014 influenza season; education and awareness of pandemic and biodefense funding, including policy ramifications of recent BARDA contract awards; education and awareness of Dengue; general issues related to NIH funding; all provisions of HR 2094 "School Access to Emergency Epinephrine Act"; all provisions of HR2985 "The Combination Drug Development Incentive Act"; S1871 "Sustainable Growth Rate (SGR) Repeal and Medicare Beneficiary Access Improvement Act of2013"; and all provisions of HR1024 and S557 "Medication Therapy Management Empowerment Act of 2013"

Education and awareness of the 2012-2013 influenza season; education and awareness of pandemic and biodefense funding; education and awareness of dengue; FDA funding; NIH funding; general issues related to diabetes awareness; all provisions of S 557 "Medication Therapy Management Empowerment Act of 2013"; all provisions of S 596 "Fostering Independence Through Technology Act of 2013"; issues related to the Independent Payment Advisory Board; general issues related to School Access to EmergencyEpinephrine; and issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine.

Education and awareness of the 2012-2013 influenza season; education and awareness of pandemic and biodefense funding; education and awareness of dengue; FDA funding; NIH funding; general issues related to diabetes awareness; all provisions of S 557 "Medication Therapy Management Empowerment Act of 2013"; all provisions of S 596 "Fostering Independence Through Technology Act of 2013"; issues related to the Independent Payment Advisory Board; general issues related to School Access to EmergencyEpinephrine; and issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine.

Education and awareness of the 2013-2014 influenza season; education and awareness of pandemic and biodefense funding, including policy ramifications of recent BARDA contract awards; education and awareness of Dengue; general issues related to NIH funding; all provisions of HR 2094 "School Access to Emergency Epinephrine Act"; all provisions of HR2985 "The Combination Drug Development Incentive Act"; S1871 "Sustainable Growth Rate (SGR) Repeal and Medicare Beneficiary Access Improvement Act of2013"; and all provisions of HR1024 and S557 "Medication Therapy Management Empowerment Act of 2013"

Education and awareness of the 2012-2013 influenza season; education and awareness of pandemic and biodefense funding; education and awareness of dengue; FDA funding; NIH funding; general issues related to diabetes awareness; all provisions of S 557 "Medication Therapy Management Empowerment Act of 2013"; all provisions of S 596 "Fostering Independence Through Technology Act of 2013"; issues related to the Independent Payment Advisory Board; general issues related to School Access to EmergencyEpinephrine; and issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine.

Education and awareness of the 2012-2013 influenza season; education and awareness of pandemic and biodefense funding; education and awareness of dengue; FDA funding; NIH funding; general issues related to diabetes awareness; all provisions of S 557 "Medication Therapy Management Empowerment Act of 2013"; all provisions of S 596 "Fostering Independence Through Technology Act of 2013"; issues related to the Independent Payment Advisory Board; general issues related to School Access to EmergencyEpinephrine; and issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine.

S. 77 "Prescription Drug and Health Improvement Act of 2013" - all provisions; S117, "Medicare Prescription Drug Price Negotiation Act of 2013" - all provisions; issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; education and awareness of the 2012-2013 influenza season; education and awareness of pandemic and biodefense funding; education and awareness of dengue; FDA funding; reauthorization of Pandemic and All HazardsPreparation Act; general issues related to the importation of pharmaceutical products; issues related to chronic disease treatment adherence with the CMS Innovation Center; general issues related to School Access to Emergency Ephinephrine; and issues related to the data exclusivity period for generic biologics.

S. 77 "Prescription Drug and Health Improvement Act of 2013" - all provisions; S117, "Medicare Prescription Drug Price Negotiation Act of 2013" - all provisions; issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; education and awareness of the 2012-2013 influenza season; education and awareness of pandemic and biodefense funding; education and awareness of dengue; FDA funding; reauthorization of Pandemic and All HazardsPreparation Act; general issues related to the importation of pharmaceutical products; issues related to chronic disease treatment adherence with the CMS Innovation Center; general issues related to School Access to Emergency Ephinephrine; and issues related to the data exclusivity period for generic biologics.

The scoring of preventive health savings including all provisions of S1422 and HR 2663 "Preventative Health Savings Act" and H.J.Res.59 - Continuing Appropriations Resolution, 2014, including funding for FDA.

Repeal and defunding efforts and general issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including the Independent Payment Advisory Board (IPAB); awareness & issues related to diabetes and patient access to diabetes care; general issues related to prescription drug safety; HR2529 "Restoring Access to Medication Act" - all provisions; HR2245 "Preserving Access to Life-Saving Medications Act of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; issues related to efforts to move pseudoephedrine products to prescription drug status; education and awareness of influenza pandemic and biodefense funding in FY2012 funding bills; education and awareness and general issues related to the reauthorization of the Pandemic and All Hazards Preparation Act; education and awareness of dengue; all provisions of S1002 "Safe Doses Act"; awareness & issues related to patient access to care for Dengue; and all provisions of draft legislation "Immunization Improvements Act of 2011."

General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" and efforts to repeal PL111-148 provisions that prohibit individuals from using Health Savings Accounts or Flexible Spending Accounts to purchase Over-The-Counter medical products, including such provisions in HR2529 "Restoring Access to Medication Act" and HR436 "Health Care Cost Reduction Act of 2012"; awareness & issues related to diabetes and patient access to diabetes care; S1002 and HR4223 "SAFE DOSES Act" - all provisions; HR2405 and S1855 "Pandemic and All Hazards Preparation Act Reauthorization of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of influenza pandemic and biodefense funding in FY2012 and related international intellectual property issues; education and awareness of dengue.

General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including issues related to the Independent Payment Advisory Board, and efforts to repeal provisions that prohibit individuals from using Health Savings Accounts or Flexible Spending Accounts to purchase Over-The-Counter medical products, including such provisions in HR2529 "Restoring Access to Medication Act" and HR436 "Health Care Cost Reduction Act of 2012"; awareness & issues related to diabetes and patient access to diabetes care; HR4223 "Strengthening and Focusing Enforcement to Deter Organized Stealing and Enhance Safety Act of 2012" or "SAFE DOSES Act" - all provisions; issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; HR2405 and S1855 "Pandemic and All Hazards Preparation Act Reauthorization of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of influenza pandemic and biodefense funding in FY2012 and related international intellectual property issues; education and awareness of dengue; and all provisions of H. Res. 295 "Promoting increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with this disease."

General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act including issues related to the Independent Payment Advisory Board; "HR4223 "Strengthening and Focusing Enforcement to Deter Organized Stealing and Enhance Safety Act of 2012" or "SAFE DOSES Act" - all provisions; issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; HR2405 and S1855 "Pandemic and All Hazards Preparation Act Reauthorization of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of pandemic and biodefense funding in FY2012 and related international intellectual property issues; and education and awareness of dengue.

General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" and efforts to repeal PL111-148 provisions that prohibit individuals from using Health Savings Accounts or Flexible Spending Accounts to purchase Over-The-Counter medical products, including such provisions in HR2529 "Restoring Access to Medication Act" and HR436 "Health Care Cost Reduction Act of 2012"; awareness & issues related to diabetes and patient access to diabetes care; S1002 and HR4223"SAFE DOSES Act" - all provisions; HR2405 and S1855 "Pandemic and All Hazards Preparation Act Reauthorization of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of influenza pandemic and biodefense funding in FY2012 and related international intellectual property issues;education and awareness of dengue.

General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act including issues related to the Independent Payment Advisory Board; "HR4223 "Strengthening and Focusing Enforcement to Deter Organized Stealing and Enhance Safety Act of 2012" or "SAFE DOSES Act" - all provisions; issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; HR2405 and S1855 "Pandemic and All Hazards Preparation ActReauthorization of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of pandemic and biodefense funding in FY2012 and related international intellectual property issues; and education and awareness of dengue.

General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including issues related to the Independent Payment Advisory Board, and efforts to repeal provisions that prohibit individuals from using Health Savings Accounts or Flexible Spending Accounts to purchase Over-The-Counter medical products, including such provisions in HR2529 "Restoring Access to Medication Act" and HR436 "Health Care Cost Reduction Act of 2012"; awareness & issues relatedto diabetes and patient access to diabetes care; HR4223 "Strengthening and Focusing Enforcement to Deter Organized Stealing and Enhance Safety Act of 2012" or "SAFE DOSES Act" - all provisions; issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; HR2405 and S1855 "Pandemic and All Hazards Preparation Act Reauthorization of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of influenza pandemic and biodefense funding in FY2012 and related international intellectual property issues; education and awareness of dengue; and all provisions of H. Res. 295 "Promoting increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with this disease."

Repeal and defunding efforts and general issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including the Independent Payment Advisory Board (IPAB); awareness & issues related to diabetes and patient access to diabetes care; general issues related to prescription drug safety; HR2529 "Restoring Access to Medication Act" - all provisions; HR2245 "Preserving Access to Life-Saving Medications Act of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; issues related to efforts to move pseudoephedrine products to prescription drug status; education and awareness of influenza pandemic and biodefense funding in FY2012 funding bills; education and awareness and general issues related to the reauthorization of the Pandemic and All Hazards Preparation Act; education and awareness of dengue; all provisions of S1002 "Safe Doses Act"; awareness & issues related to patient access to care for Dengue; and all provisions of draft legislation "Immunization Improvements Act of 2011."

Repeal and defunding efforts and general issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including the Independent Payment Advisory Board (IPAB); awareness & issues related to diabetes and patient access to diabetes care; general issues related to prescription drug safety; HR2529 "Restoring Access to Medication Act" - all provisions; HR2245 "Preserving Access to Life-Saving Medications Act of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; issues related to efforts to move pseudoephedrine products to prescription drug status; education and awareness of influenza pandemic and biodefense funding in FY2012 funding bills; education and awareness and general issues related to the reauthorization of the Pandemic and All Hazards Preparation Act; education and awareness of dengue; all provisions of S1002 "Safe Doses Act"; awareness & issues related to patient access to care for Dengue; and all provisions of draft legislation "Immunization Improvements Act of 2011."

General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including issues related to the Independent Payment Advisory Board, and efforts to repeal provisions that prohibit individuals from using Health Savings Accounts or Flexible Spending Accounts to purchase Over-The-Counter medical products, including such provisions in HR2529 "Restoring Access to Medication Act" and HR436 "Health Care Cost Reduction Act of 2012"; awareness & issues related to diabetes and patient access to diabetes care; HR4223 "Strengthening and Focusing Enforcement to Deter Organized Stealing and Enhance Safety Act of 2012" or "SAFE DOSES Act" - all provisions; issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; HR2405 and S1855 "Pandemic and All Hazards Preparation Act Reauthorization of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of influenza pandemic and biodefense funding in FY2012 and related international intellectual property issues; education and awareness of dengue; and all provisions of H. Res. 295 "Promoting increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with this disease."

General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act including issues related to the Independent Payment Advisory Board; "HR4223 "Strengthening and Focusing Enforcement to Deter Organized Stealing and Enhance Safety Act of 2012" or "SAFE DOSES Act" - all provisions; issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; HR2405 and S1855 "Pandemic and All Hazards Preparation Act Reauthorization of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of pandemic and biodefense funding in FY2012 and related international intellectual property issues; and education and awareness of dengue.

General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" and efforts to repeal PL111-148 provisions that prohibit individuals from using Health Savings Accounts or Flexible Spending Accounts to purchase Over-The-Counter medical products, including such provisions in HR2529 "Restoring Access to Medication Act" and HR436 "Health Care Cost Reduction Act of 2012"; awareness & issues related to diabetes and patient access to diabetes care; S1002 and HR4223"SAFE DOSES Act" - all provisions; HR2405 and S1855 "Pandemic and All Hazards Preparation Act Reauthorization of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of influenza pandemic and biodefense funding in FY2012 and related international intellectual property issues;education and awareness of dengue.

General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act including issues related to the Independent Payment Advisory Board; "HR4223 "Strengthening and Focusing Enforcement to Deter Organized Stealing and Enhance Safety Act of 2012" or "SAFE DOSES Act" - all provisions; issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; HR2405 and S1855 "Pandemic and All Hazards Preparation ActReauthorization of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of pandemic and biodefense funding in FY2012 and related international intellectual property issues; and education and awareness of dengue.

General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including issues related to the Independent Payment Advisory Board, and efforts to repeal provisions that prohibit individuals from using Health Savings Accounts or Flexible Spending Accounts to purchase Over-The-Counter medical products, including such provisions in HR2529 "Restoring Access to Medication Act" and HR436 "Health Care Cost Reduction Act of 2012"; awareness & issues relatedto diabetes and patient access to diabetes care; HR4223 "Strengthening and Focusing Enforcement to Deter Organized Stealing and Enhance Safety Act of 2012" or "SAFE DOSES Act" - all provisions; issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; HR2405 and S1855 "Pandemic and All Hazards Preparation Act Reauthorization of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of influenza pandemic and biodefense funding in FY2012 and related international intellectual property issues; education and awareness of dengue; and all provisions of H. Res. 295 "Promoting increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with this disease."

General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" and efforts to repeal PL111-148 provisions that prohibit individuals from using Health Savings Accounts or Flexible Spending Accounts to purchase Over-The-Counter medical products, including such provisions in HR2529 "Restoring Access to Medication Act" and HR436 "Health Care Cost Reduction Act of 2012"; awareness & issues related to diabetes and patient access to diabetes care; S1002 and HR4223 "SAFE DOSES Act" - all provisions; HR2405 and S1855 "Pandemic and All Hazards Preparation Act Reauthorization of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of influenza pandemic and biodefense funding in FY2012 and related international intellectual property issues; education and awareness of dengue.

General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including issues related to the Independent Payment Advisory Board, and efforts to repeal provisions that prohibit individuals from using Health Savings Accounts or Flexible Spending Accounts to purchase Over-The-Counter medical products, including such provisions in HR2529 "Restoring Access to Medication Act" and HR436 "Health Care Cost Reduction Act of 2012"; awareness & issues related to diabetes and patient access to diabetes care; HR4223 "Strengthening and Focusing Enforcement to Deter Organized Stealing and Enhance Safety Act of 2012" or "SAFE DOSES Act" - all provisions; issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; HR2405 and S1855 "Pandemic and All Hazards Preparation Act Reauthorization of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of influenza pandemic and biodefense funding in FY2012 and related international intellectual property issues; education and awareness of dengue; and all provisions of H. Res. 295 "Promoting increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with this disease."

General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act including issues related to the Independent Payment Advisory Board; "HR4223 "Strengthening and Focusing Enforcement to Deter Organized Stealing and Enhance Safety Act of 2012" or "SAFE DOSES Act" - all provisions; issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; HR2405 and S1855 "Pandemic and All Hazards Preparation ActReauthorization of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of pandemic and biodefense funding in FY2012 and related international intellectual property issues; and education and awareness of dengue.

General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" and efforts to repeal PL111-148 provisions that prohibit individuals from using Health Savings Accounts or Flexible Spending Accounts to purchase Over-The-Counter medical products, including such provisions in HR2529 "Restoring Access to Medication Act" and HR436 "Health Care Cost Reduction Act of 2012"; awareness & issues related to diabetes and patient access to diabetes care; S1002 and HR4223"SAFE DOSES Act" - all provisions; HR2405 and S1855 "Pandemic and All Hazards Preparation Act Reauthorization of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of influenza pandemic and biodefense funding in FY2012 and related international intellectual property issues;education and awareness of dengue.

General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act including issues related to the Independent Payment Advisory Board; "HR4223 "Strengthening and Focusing Enforcement to Deter Organized Stealing and Enhance Safety Act of 2012" or "SAFE DOSES Act" - all provisions; issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; HR2405 and S1855 "Pandemic and All Hazards Preparation Act Reauthorization of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of pandemic and biodefense funding in FY2012 and related international intellectual property issues; and education and awareness of dengue.

General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including issues related to the Independent Payment Advisory Board, and efforts to repeal provisions that prohibit individuals from using Health Savings Accounts or Flexible Spending Accounts to purchase Over-The-Counter medical products, including such provisions in HR2529 "Restoring Access to Medication Act" and HR436 "Health Care Cost Reduction Act of 2012"; awareness & issues relatedto diabetes and patient access to diabetes care; HR4223 "Strengthening and Focusing Enforcement to Deter Organized Stealing and Enhance Safety Act of 2012" or "SAFE DOSES Act" - all provisions; issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; HR2405 and S1855 "Pandemic and All Hazards Preparation Act Reauthorization of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of influenza pandemic and biodefense funding in FY2012 and related international intellectual property issues; education and awareness of dengue; and all provisions of H. Res. 295 "Promoting increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with this disease."

General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" and efforts to repeal PL111-148 provisions that prohibit individuals from using Health Savings Accounts or Flexible Spending Accounts to purchase Over-The-Counter medical products, including such provisions in HR2529 "Restoring Access to Medication Act" and HR436 "Health Care Cost Reduction Act of 2012"; awareness & issues related to diabetes and patient access to diabetes care; S1002 and HR4223 "SAFE DOSES Act" - all provisions; HR2405 and S1855 "Pandemic and All Hazards Preparation Act Reauthorization of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of influenza pandemic and biodefense funding in FY2012 and related international intellectual property issues; education and awareness of dengue.

Reauthorization of the Prescription Drug User Fee Act (PDUFA) including potential amendments and all provisions of HR5651 "Food and Drug Administration Reform Act of 2012" and S3187 "Food and Drug Administration Safety and Innovation Act"

General issues related to prescription drug supply chain, including importation safety, foreign inspections, track and trace, and drug shortage including related amendments to HR5651 "Food and Drug Administration Reform Act of 2012" and S3187 "Food and Drug Administration Safety and Innovation Act"

General issues related to prescription drug supply chain, including importation safety, foreign inspections, track and trace, and drug shortage, including related amendments to HR5651 "Food and Drug Administration Reform Act of 2012" and S3187 "Food and Drug Administration Safety and Innovation Act"

Reauthorization of the Prescription Drug User Fee Act (PDUFA) including potential amendments and all provisions of HR5651 "Food and Drug Administration Reform Act of 2012" and S3187 "Food and Drug Administration Safety and Innovation Act"

General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" and efforts to repeal PL111-148 provisions that prohibit individuals from using Health Savings Accounts or Flexible Spending Accounts to purchase Over-The-Counter medical products, including such provisions in HR2529 "Restoring Access to Medication Act" and HR436 "Health Care Cost Reduction Act of 2012"; awareness & issues related to diabetes and patient access to diabetes care; S1002 and HR4223 "SAFE DOSES Act" - all provisions; HR2405 and S1855 "Pandemic and All Hazards Preparation Act Reauthorization of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of influenza pandemic and biodefense funding in FY2012 and related international intellectual property issues; education and awareness of dengue.

Repeal and defunding efforts and general issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including the Independent Payment Advisory Board (IPAB); awareness & issues related to diabetes and patient access to diabetes care; general issues related to prescription drug safety; HR2529 "Restoring Access to Medication Act" - all provisions; HR2245 "Preserving Access to Life-Saving Medications Act of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; issues related to efforts to move pseudoephedrine products to prescription drug status; education and awareness of influenza pandemic and biodefense funding in FY2012 funding bills; education and awareness and general issues related to the reauthorization of the Pandemic and All Hazards Preparation Act; education and awareness of dengue; all provisions of S1002 "Safe Doses Act"; awareness & issues related to patient access to care for Dengue; and all provisions of draft legislation "Immunization Improvements Act of 2011."

General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" and efforts to repeal PL111-148 provisions that prohibit individuals from using Health Savings Accounts or Flexible Spending Accounts to purchase Over-The-Counter medical products, including such provisions in HR2529 "Restoring Access to Medication Act" and HR436 "Health Care Cost Reduction Act of 2012"; awareness & issues related to diabetes and patient access to diabetes care; S1002 and HR4223"SAFE DOSES Act" - all provisions; HR2405 and S1855 "Pandemic and All Hazards Preparation Act Reauthorization of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of influenza pandemic and biodefense funding in FY2012 and related international intellectual property issues;education and awareness of dengue.

General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including issues related to the Independent Payment Advisory Board, and efforts to repeal provisions that prohibit individuals from using Health Savings Accounts or Flexible Spending Accounts to purchase Over-The-Counter medical products, including such provisions in HR2529 "Restoring Access to Medication Act" and HR436 "Health Care Cost Reduction Act of 2012"; awareness & issues relatedto diabetes and patient access to diabetes care; HR4223 "Strengthening and Focusing Enforcement to Deter Organized Stealing and Enhance Safety Act of 2012" or "SAFE DOSES Act" - all provisions; issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; HR2405 and S1855 "Pandemic and All Hazards Preparation Act Reauthorization of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of influenza pandemic and biodefense funding in FY2012 and related international intellectual property issues; education and awareness of dengue; and all provisions of H. Res. 295 "Promoting increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with this disease."

General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" and efforts to repeal PL111-148 provisions that prohibit individuals from using Health Savings Accounts or Flexible Spending Accounts to purchase Over-The-Counter medical products, including such provisions in HR2529 "Restoring Access to Medication Act" and HR436 "Health Care Cost Reduction Act of 2012"; awareness & issues related to diabetes and patient access to diabetes care; S1002 and HR4223"SAFE DOSES Act" - all provisions; HR2405 and S1855 "Pandemic and All Hazards Preparation Act Reauthorization of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of influenza pandemic and biodefense funding in FY2012 and related international intellectual property issues;education and awareness of dengue.

General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including issues related to the Independent Payment Advisory Board, and efforts to repeal provisions that prohibit individuals from using Health Savings Accounts or Flexible Spending Accounts to purchase Over-The-Counter medical products, including such provisions in HR2529 "Restoring Access to Medication Act" and HR436 "Health Care Cost Reduction Act of 2012"; awareness & issues related to diabetes and patient access to diabetes care; HR4223 "Strengthening and Focusing Enforcement to Deter Organized Stealing and Enhance Safety Act of 2012" or "SAFE DOSES Act" - all provisions; issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; HR2405 and S1855 "Pandemic and All Hazards Preparation Act Reauthorization of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of influenza pandemic and biodefense funding in FY2012 and related international intellectual property issues; education and awareness of dengue; and all provisions of H. Res. 295 "Promoting increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with this disease."

General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" and efforts to repeal PL111-148 provisions that prohibit individuals from using Health Savings Accounts or Flexible Spending Accounts to purchase Over-The-Counter medical products, including such provisions in HR2529 "Restoring Access to Medication Act" and HR436 "Health Care Cost Reduction Act of 2012"; awareness & issues related to diabetes and patient access to diabetes care; S1002 and HR4223 "SAFE DOSES Act" - all provisions; HR2405 and S1855 "Pandemic and All Hazards Preparation Act Reauthorization of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of influenza pandemic and biodefense funding in FY2012 and related international intellectual property issues; education and awareness of dengue.

General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including issues related to the Independent Payment Advisory Board, and efforts to repeal provisions that prohibit individuals from using Health Savings Accounts or Flexible Spending Accounts to purchase Over-The-Counter medical products, including such provisions in HR2529 "Restoring Access to Medication Act" and HR436 "Health Care Cost Reduction Act of 2012"; awareness & issues related to diabetes and patient access to diabetes care; HR4223 "Strengthening and Focusing Enforcement to Deter Organized Stealing and Enhance Safety Act of 2012" or "SAFE DOSES Act" - all provisions; issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; HR2405 and S1855 "Pandemic and All Hazards Preparation Act Reauthorization of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of influenza pandemic and biodefense funding in FY2012 and related international intellectual property issues; education and awareness of dengue; and all provisions of H. Res. 295 "Promoting increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with this disease."

General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including issues related to the Independent Payment Advisory Board, and efforts to repeal provisions that prohibit individuals from using Health Savings Accounts or Flexible Spending Accounts to purchase Over-The-Counter medical products, including such provisions in HR2529 "Restoring Access to Medication Act" and HR436 "Health Care Cost Reduction Act of 2012"; awareness & issues relatedto diabetes and patient access to diabetes care; HR4223 "Strengthening and Focusing Enforcement to Deter Organized Stealing and Enhance Safety Act of 2012" or "SAFE DOSES Act" - all provisions; issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; HR2405 and S1855 "Pandemic and All Hazards Preparation Act Reauthorization of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of influenza pandemic and biodefense funding in FY2012 and related international intellectual property issues; education and awareness of dengue; and all provisions of H. Res. 295 "Promoting increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with this disease."

General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" and efforts to repeal PL111-148 provisions that prohibit individuals from using Health Savings Accounts or Flexible Spending Accounts to purchase Over-The-Counter medical products, including such provisions in HR2529 "Restoring Access to Medication Act" and HR436 "Health Care Cost Reduction Act of 2012"; awareness & issues related to diabetes and patient access to diabetes care; S1002 and HR4223 "SAFE DOSES Act" - all provisions; HR2405 and S1855 "Pandemic and All Hazards Preparation Act Reauthorization of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of influenza pandemic and biodefense funding in FY2012 and related international intellectual property issues; education and awareness of dengue.

General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" and efforts to repeal PL111-148 provisions that prohibit individuals from using Health Savings Accounts or Flexible Spending Accounts to purchase Over-The-Counter medical products, including such provisions in HR2529 "Restoring Access to Medication Act" and HR436 "Health Care Cost Reduction Act of 2012"; awareness & issues related to diabetes and patient access to diabetes care; S1002 and HR4223"SAFE DOSES Act" - all provisions; HR2405 and S1855 "Pandemic and All Hazards Preparation Act Reauthorization of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of influenza pandemic and biodefense funding in FY2012 and related international intellectual property issues;education and awareness of dengue.

Comparative effectiveness, including issues related to the Patient Centered Research Insitute, issues related to limitations on the use of Health Savings Accounts for over-the-counter medicines, repeal and defunding efforts, & general issues regarding implementation of HR3590 "The Patient Protection and Affordable Care Act" including the Medication Therapy Management Program transitions of care; awareness and issues related to patient access to diabetes care; awareness and issues related to patient access to atrial fibrillation care; all provisions of S668 "Health Care Bureaucrats Elimination Act" and HR452 "Medicare Decisions Accountability Act of 2011"; issues related to importation of prescription medicines; issues related to efforts to move pseudoephedrine products to prescription drug status; section 401 of S174 "Healthy Lifestyles and Prevention (HeLP) America Act"; and issues related to pandemic influenza and biodefense funding

Comparative effectiveness, including issues related to the Patient Centered Research Insitute, issues related to limitations on the use of Health Savings Accounts for over-the-counter medicines, repeal and defunding efforts, & general issues regarding implementation of HR3590 "The Patient Protection and Affordable Care Act" including the Medication Therapy Management Program transitions of care; awareness and issues related to patient access to diabetes care; awareness and issues related to patient access to atrial fibrillation care; all provisions of S668 "Health Care Bureaucrats Elimination Act" and HR452 "Medicare Decisions Accountability Act of 2011"; issues related to importation of prescription medicines; issues related to efforts to move pseudoephedrine products to prescription drug status; section 401 of S174 "Healthy Lifestyles and Prevention (HeLP) America Act"; and issues related to pandemic influenza and biodefense funding

Repeal and defunding efforts and general issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including all provisions of HR2529 "Restoring Access to Medication Act", the Medication Therapy Management Program, and the Independent Payment Advisory Board (IPAB); awareness and issues related to diabetes and patient access to diabetes care; awareness & issues related to patient access to atrial fibrillation care, including all provisions in HRes295 "Promoting increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with this disease", and S Res 243 "A resolution promoting increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with the disease"; issues related to efforts to move pseudoephedrine products to prescription drug status; education and awareness of influenza pandemic and biodefense funding in FY2012 funding bills; intellectual propterty issues in the WHO global pandemic vaccine allocation plans; education and awareness and general issues related to the reauthorization of the Pandemic and All Hazards Preparation Act; education and awareness of dengue; general issues related to prescription drug safety and the importation of prescription drugs; and all provisions of S1002 "Safe Doses Act".

Repeal and defunding efforts and general issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including all provisions of HR605 and S312 "Patients' Freedom to Choose Act," the Medication Therapy Management Program, transitions of care, and the Independent Payment Advisory Board (IPAB); awareness and issues related to patient access to diabetes care; awareness & issues related to patient access to atrial fibrillation care, including all provisions in HRes295 "Promoting increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with this disease", issues related to efforts to move pseudoephedrine products to prescription drug status; education and awareness of influenza pandemic and biodefense funding in FY2012 funding bills; intellectual propterty issues in the WHO global pandemic vaccine allocation plans; education and awareness and general issues related to the reauthorization of the Pandemic and All Hazards Preparation Act; education and awareness of the company's global Access to Medicines Program; education and awareness of dengue; issues related to the Section 317 Program for vaccines; general issues related to prescription drug safety; and all provisions of S1002 "Safe Doses Act".

Repeal and defunding efforts and general issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including all provisions of HR2529 "Restoring Access to Medication Act", the Medication Therapy Management Program, and the Independent Payment Advisory Board (IPAB); awareness and issues related to diabetes and patient access to diabetes care; awareness & issues related to patient access to atrial fibrillation care, including all provisions in HRes295 "Promoting increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with this disease", and S Res 243 "A resolution promoting increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with the disease"; issues related to efforts to move pseudoephedrine products to prescription drug status; education and awareness of influenza pandemic and biodefense funding in FY2012 funding bills; intellectual propterty issues in the WHO global pandemic vaccine allocation plans; education and awareness and general issues related to the reauthorization of the Pandemic and All Hazards Preparation Act; education and awareness of dengue; general issues related to prescription drug safety and the importation of prescription drugs; and all provisions of S1002 "Safe Doses Act".

Repeal and defunding efforts and general issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including all provisions of HR605 and S312 "Patients' Freedom to Choose Act," the Medication Therapy Management Program, transitions of care, and the Independent Payment Advisory Board (IPAB); awareness and issues related to patient access to diabetes care; awareness & issues related to patient access to atrial fibrillation care, including all provisions in HRes295 "Promoting increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with this disease", issues related to efforts to move pseudoephedrine products to prescription drug status; education and awareness of influenza pandemic and biodefense funding in FY2012 funding bills; intellectual propterty issues in the WHO global pandemic vaccine allocation plans; education and awareness and general issues related to the reauthorization of the Pandemic and All Hazards Preparation Act; education and awareness of the company's global Access to Medicines Program; education and awareness of dengue; issues related to the Section 317 Program for vaccines; general issues related to prescription drug safety; and all provisions of S1002 "Safe Doses Act".

Repeal and defunding efforts and general issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including all provisions of HR605 and S312 "Patients' Freedom to Choose Act," the Medication Therapy Management Program, transitions of care, and the Independent Payment Advisory Board (IPAB); awareness and issues related to patient access to diabetes care; awareness & issues related to patient access to atrial fibrillation care, including all provisions in HRes295 "Promoting increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with this disease", issues related to efforts to move pseudoephedrine products to prescription drug status; education and awareness of influenza pandemic and biodefense funding in FY2012 funding bills; intellectual propterty issues in the WHO global pandemic vaccine allocation plans; education and awareness and general issues related to the reauthorization of the Pandemic and All Hazards Preparation Act; education and awareness of the company's global Access to Medicines Program; education and awareness of dengue; issues related to the Section 317 Program for vaccines; general issues related to prescription drug safety; and all provisions of S1002 "Safe Doses Act".

HR3692 "To provide affordable, quality health care for all Americans and reduce the growth in healht care spending, and for other purposes"; HR 4872 "Health Care and Education Reconcilliation Act of 2010"; HR3590 "The Patient Protection and Affordable Care Act" - provisions related to follow-on biologics, comparative effectiveness research, 340B programs and the Independent Payment Advisory Board; issues related to prescription drug safety and heparin; issues related to cancer awareness and access to treatment.

All provisions of S369 "Preserve Access to Affordable Generics Act" and including this bill as amended to be included in S3677 "Financial Services and General Government Appropriations Act, 2011"

All provisions of S369 "Preserve Access to Affordable Generics Act" and including this bill as amended to be included in S3677 "Financial Services and General Government Appropriations Act, 2011"; and S515 " Patent Reform Act of 2009" - all provisions.

S369 "Protecting Access to Affordable Generic Drugs Act of 2009" - all provisions; S515 "Patent Reform Act of 2009 " - all provisions

All provisions of S369 "Preserve Access to Affordable Generics Act" and including this bill as amended to be included in S3677 "Financial Services and General Government Appropriations Act, 2011"; and S515 " Patent Reform Act of 2009" - all provisions.

All provisions of S369 "Preserve Access to Affordable Generics Act" and including this bill as amended to be included in S3677 "Financial Services and General Government Appropriations Act, 2011"

All provisions of S369 "Preserve Access to Affordable Generics Act" and including this bill as amended to be included in S3677 "Financial Services and General Government Appropriations Act, 2011"; and S515 " Patent Reform Act of 2009" - all provisions.

S369 "Protecting Access to Affordable Generic Drugs Act of 2009" - all provisions; S515 "Patent Reform Act of 2009 " - all provisions

Comparative effectiveness research, including issues related to the Patient Centered Research Institute, and general issues regarding the implementation of HR3590 "The Patient Protection and Affordable Care Act"; information and awareness of the availability of new treatment options for cancer patients; prescription drug safety and heparin including related issues through a follow-on biologics regulatory pathway; issues related to influenza vaccine coverage in the Medicare Part D program; awareness and issues related to patient Access to diabetes care

Comparative effectiveness research and general issues regarding the implementation of HR3590 "The Patient Protection and Affordable Care Act"; information and awareness of a Community Health Liaison Program; information and awareness of the availability of new treatment options for cancer patients; prescription drug safety and heparin including related issues through a follow on biologics regulatory pathway

HR3692 "To provide affordable, quality health care for all Americans and reduce the growth in healht care spending, and for other purposes"; HR 4872 "Health Care and Education Reconcilliation Act of 2010"; HR3590 "The Patient Protection and Affordable Care Act" - provisions related to follow-on biologics, comparative effectiveness research, 340B programs and the Independent Payment Advisory Board; issues related to prescription drug safety and heparin; issues related to cancer awareness and access to treatment.

Comparative effectiveness, including issues realted to the Patient Centered Research Institute, and general issues regarding implementation of HR3590 "The Patient Protection and Affordable Care Act"; information and awareness of the availability of new treatment options for cancer patient; and awareness and issues related to patient access to diabetes care.

All provisions of S369 "Protecting Access to Affordable Generic Drugs Act of 2009" and HR1706 "Protecting Consumer Access to Generic Drugs Act of 2009"; all provisions of S515 "The Patent Reform Act of 2009" and HR1260 "The Patent Reform Act of 2009"

Coverage and payment issues for pharmaceuticals under consideration for draft legislation for healthcare reform; issues related to the importation of prescription drugs in amendments to the draft legislation "Affordable Health Choices Act"; issues related to a regulatory pathway and reimburesment for follow on biologics, including such provisions in HR 1548 "Pathway for Biosimilars Act"; issues related to awareness of the company's Access to Medicines Program; all provisions of H. Res. 231 "Supporting the goals and ideals of 'Deep Vein Thrombosis Awareness Month'"; general issues related to the Medicare Part D program

All provisions of S369 "Protecting Access to Affordable Generic Drugs Act of 2009" and HR1706 "Protecting Consumer Access to Generic Drugs Act of 2009"; all provisions of S515 "The Patent Reform Act of 2009" and HR1260 "The Patent Reform Act of 2009"

All provisions of S369 "Protecting Access to Affordable Generic Drugs Act of 2009" and HR1706 "Protecting Consumer Access to Generic Drugs Act of 2009"; all provisions of S515 "The Patent Reform Act of 2009"; and issues related to a regulatory pathway and reimbursement for follow-on biologics

Provisions and issues related to coverage and payment pharmaceuticals, provisions related to intellectual property and issues related to a regulatory pathway and reimbursement for follow-on biologics, issues related to the importation of prescription drugs, issues related to cancer awareness and access to treatment, issues related to the coordination of care, and issues related to the 340B federal Safety Net Drug Pricing Program including such provisions included or under consideration in draft health care reform legislation "America's Healthy Future Act," and in HR3200 "America's Affordable Health Choices Act," and S1679 "Affordable Health Choices Act"; General issues related to the Medicare Part D program and issues related to awareness of atrial fibrillation and access to treatment.; All provisions of HR2502 "To amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research and to amend the Internal Revenue Code of 1986 to establish a Comparative Effectiveness Research Trust Fund, and for other purposes"; All provisions of H. Res. 231 "Supporting the goals and ideals of 'Deep Vein Thrombosis Awareness Month'"

Provisions and issues related to coverage and payment pharmaceuticals, provisions related to intellectual property and issues related to a regulatory pathway and reimbursement for follow-on biologics, issues related to the importation of prescription drugs, issues related to cancer awareness and access to treatment, issues related to the coordination of care, and issues related to the 340B federal Safety Net Drug Pricing Program including such provisions included or under consideration in draft health care reform legislation "America's Healthy Future Act," and in HR3200 "America's Affordable Health Choices Act," and S1679 "Affordable Health Choices Act"; General issues related to the Medicare Part D program and issues related to awareness of atrial fibrillation and access to treatment.; All provisions of HR2502 "To amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research and to amend the Internal Revenue Code of 1986 to establish a Comparative Effectiveness Research Trust Fund, and for other purposes"; All provisions of H. Res. 231 "Supporting the goals and ideals of 'Deep Vein Thrombosis Awareness Month'"

Provisions and issues related to patient access to and the coverage, payment and pricing of pharmaceuticals, provisions related to intellectual property and issues related to a regulatory pathway and reimbursement for follow-on biologics, issues related to cancer awareness and access to treatment, issues and provisions related to the 340B federal Safety Net Drug Pricing Program, issues and provisions related to comparative effectiveness, and issues and provisions related to the Independent Medicare Advisory Committee in HR3590"The Patient Protection and Affordable Care Act." All provisions of SAmdt2952 to HR3590. General issues related to the Medicare Part D program including patient access to pharmaceuticals, issues related to awareness of atrial fibrillation and access to treatment, issues related to cancer awareness and access to treatment; and H Res 231 "Supporting the goals and ideals of 'Deep Vein Thrombosis Awareness Month' and 'National DVT Screening Day' and supporting efforts to educate the public about deep vein thrombosis, in memory of former Representative Jennifer Dunn."

Coverage and payment issues for pharmaceuticals under consideration for draft legislation for healthcare reform; issues related to the importation of prescription drugs in amendments to the draft legislation "Affordable Health Choices Act"; issues related to a regulatory pathway and reimburesment for follow on biologics, including such provisions in HR 1548 "Pathway for Biosimilars Act"; issues related to awareness of the company's Access to Medicines Program; all provisions of H. Res. 231 "Supporting the goals and ideals of 'Deep Vein Thrombosis Awareness Month'"; general issues related to the Medicare Part D program

Provisions and issues related to coverage and payment pharmaceuticals, provisions related to intellectual property and issues related to a regulatory pathway and reimbursement for follow-on biologics, issues related to the importation of prescription drugs, issues related to cancer awareness and access to treatment, issues related to the coordination of care, and issues related to the 340B federal Safety Net Drug Pricing Program including such provisions included or under consideration in draft health care reform legislation "America's Healthy Future Act," and in HR3200 "America's Affordable Health Choices Act," and S1679 "Affordable Health Choices Act"; General issues related to the Medicare Part D program and issues related to awareness of atrial fibrillation and access to treatment.; All provisions of HR2502 "To amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research and to amend the Internal Revenue Code of 1986 to establish a Comparative Effectiveness Research Trust Fund, and for other purposes"; All provisions of H. Res. 231 "Supporting the goals and ideals of 'Deep Vein Thrombosis Awareness Month'"

Provisions and issues related to coverage and payment pharmaceuticals, provisions related to intellectual property and issues related to a regulatory pathway and reimbursement for follow-on biologics, issues related to the importation of prescription drugs, issues related to cancer awareness and access to treatment, issues related to the coordination of care, and issues related to the 340B federal Safety Net Drug Pricing Program including such provisions included or under consideration in draft health care reform legislation "America's Healthy Future Act," and in HR3200 "America's Affordable Health Choices Act," and S1679 "Affordable Health Choices Act"; General issues related to the Medicare Part D program and issues related to awareness of atrial fibrillation and access to treatment.; All provisions of HR2502 "To amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research and to amend the Internal Revenue Code of 1986 to establish a Comparative Effectiveness Research Trust Fund, and for other purposes"; All provisions of H. Res. 231 "Supporting the goals and ideals of 'Deep Vein Thrombosis Awareness Month'"

All provisions of S369 "Protecting Access to Affordable Generic Drugs Act of 2009" and HR1706 "Protecting Consumer Access to Generic Drugs Act of 2009"; all provisions of S515 "The Patent Reform Act of 2009" and HR1260 "The Patent Reform Act of 2009"

All provisions of S369 "Protecting Access to Affordable Generic Drugs Act of 2009" and HR1706 "Protecting Consumer Access to Generic Drugs Act of 2009"; all provisions of S515 "The Patent Reform Act of 2009"; and issues related to a regulatory pathway and reimbursement for follow-on biologics

All provisions of S369 "Protecting Access to Affordable Generic Drugs Act of 2009" and HR1706 "Protecting Consumer Access to Generic Drugs Act of 2009"; all provisions of S515 "The Patent Reform Act of 2009"; and issues related to a regulatory pathway and reimbursement for follow-on biologics

All provisions of S369 "Protecting Access to Affordable Generic Drugs Act of 2009" and HR1706 "Protecting Consumer Access to Generic Drugs Act of 2009"; all provisions of S515 "The Patent Reform Act of 2009" and HR1260 "The Patent Reform Act of 2009"

Provisions and issues related to patient access to and the coverage, payment and pricing of pharmaceuticals, provisions related to intellectual property and issues related to a regulatory pathway and reimbursement for follow-on biologics, issues related to cancer awareness and access to treatment, issues and provisions related to the 340B federal Safety Net Drug Pricing Program, issues and provisions related to comparative effectiveness, and issues and provisions related to the Independent Medicare Advisory Committee in HR3590"The Patient Protection and Affordable Care Act." All provisions of SAmdt2952 to HR3590. General issues related to the Medicare Part D program including patient access to pharmaceuticals, issues related to awareness of atrial fibrillation and access to treatment, issues related to cancer awareness and access to treatment; and H Res 231 "Supporting the goals and ideals of 'Deep Vein Thrombosis Awareness Month' and 'National DVT Screening Day' and supporting efforts to educate the public about deep vein thrombosis, in memory of former Representative Jennifer Dunn."

Deep Vein Thrombosis (DVT) awareness and quality of care; DVT Call To Action; provisions related to transition rules for follow-on biologics in S 623 "Access to Life-Saving Medicine Act", HR 1956 "Patient Protection and Innovative Biologic Medicines Act of 2007", and S 1695 "Biologics Price Competition and Innovation Act of 2007"; awareness of the Together Rx Access program; awareness of the Access to Medicines Program; HR 1585 and S567, "National Defense Authorization Act for FY2008"; HR 4896 "National Defense Authorization Act for FY2008": provisions related to procurement and reimbursement for services by the TRICARE system and the quality of healthcare delivered by the Defense Health System.; issues related to the 340B federal drug pricing program

Deep Vein Thrombosis awareness; issues related to follow-on biologics included all related provisions in HR 1956 "Patient Protection and Innovative Biologic Medicines Act of 2007", and S 1695 "Biologics Price Competition and Innovation Act of 2007"; comparative effectiveness; the Together Rx Access program; HR 1585 and S567, "National Defense Authorization Act for FY2008"; HR 3222 and HR 2764, "Department of Defense Appropriations Act, 2008", and HR4986, "National Defense Authorization Act for Fiscal Year 2008": provisions related to procurement and reimbursement for services by the TRICARE system and the quality of healthcare delivered by the Defense Health System

Deep Vein Thrombosis (DVT) awareness and quality of care; DVT Call to Action; provisions related to transition rules for follow-on biologics in S 623 "Access to Life-Saving Medicine Act", HR 1956 "Patient Protection and Innovative Biologic Medicines Act of 2007", and S 1695 "Biologics Price Competition and Innovation Act of 2007"; awareness of the Together Rx Access program; awareness of the Access to Medicines Program; HR 1585 and S567, "National Defense Authorization Act for FY2008"; HR4896 "National Defense Authorization Act for FY2008": provisions related to procurement and reimbursement for services by the TRICARE system and the quality of healthcare delivered by the Defense Health System; issues related to the 340B federal drug pricing program.